Long-term benefits of omalizumab in a patient with severe non-allergic asthma

INTRODUCTION: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy. CASE PRESENTATION: We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzella, Francesco, Piro, Roberto, Facciolongo, Nicola, Castagnetti, Claudia, Simonazzi, Anna, Zucchi, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126749/
https://www.ncbi.nlm.nih.gov/pubmed/21609447
http://dx.doi.org/10.1186/1710-1492-7-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126749/
https://www.ncbi.nlm.nih.gov/pubmed/21609447
http://dx.doi.org/10.1186/1710-1492-7-9

Ejemplares similares